Strides Pharma Science Ltd on Tuesday said it will immediately launch its generic Molnupiravir, indicated for high-risk adult patients with COVID-19, in India under the brand Stripiravir. The company has received Emergency Use Authorisation from the Drugs Controller General of India (DCGI) to launch Molnupiravir 200mg, an oral medication for COVID-19, in India.In a statement, Strides said it will “immediately launch Molnupiravir in India under its brand Stripiravir”.The company is commercialising the product with a group integrated supply chain for Active Pharmaceutical Ingredients and solid oral dosage from its large-scale WHO Pre-Qualified (PQ) manufacturing capacities, it added.
“We are delighted to receive the DCGI approval for launching Molnupiravir, which has shown promising results in several clinical studies. The product provides therapeutic benefit to the patients with mild-to-moderate COVID symptoms and can be administered at home,” Strides Pharma Science Ltd Managing Director and CEO R Ananthanarayanan said.
With the emergence of the new variants, he said, “we believe Molnupiravir will benefit the broad population, which could be at risk due to COVID-19. We remain committed in our fight against this global pandemic”.Indian authorities granted restricted emergency use approval to Molnupiravir for the treatment of adult patients with COVID-19 and who have a high risk of progression of the disease.
Strides said Molnupiravir has been granted approval by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) as a safe and effective medication for patients with mild to moderate cases of COVID-19. It also recently received the USFDA’s Emergency Use Authorisation
- WHO counts 18 million virus cases last week as omicron slows - January 19, 2022
- Diet & Nutrition plan for a Head and Neck Cancer Patient - January 17, 2022
- COVID-19: HC urged to direct govt to give road map to vaccinate kids of 12 yrs and below - January 17, 2022
- 2,500 Delhi Police personnel infected, 767 cured of Covid since January 1 - January 17, 2022
- AstraZeneca vaccine trials show 3 doses give good protection against Omicron: Serum CEO - January 13, 2022
- Omicron Alert: FFD Launches Free Helpline For Diabetics - January 13, 2022
- Alkem Laboratories to Launch State of the Art Technology for Diabetic Foot Ulcer Management - January 13, 2022
- Metropolis Healthcare launches the 3rd edition of MedEngage Scholarship program to support aspiring young medical students - January 12, 2022
- Infections could surge 6 times higher due to omicron: Russia - January 12, 2022
- Makar Sankranti: Odisha bans religious gatherings; no holy dip at Haridwar - January 12, 2022